STAT3 and ovarian carcinoma: We have previously demonstrated that constitutive activation of STAT3 was present in ovarian cancer cell lines but not in normal ovarian surface epithelial cells [39], making selective STAT3 inhibition an excellent candidate for ovarian cancer treatment.